221 related articles for article (PubMed ID: 28245391)
21. [Prognostic value of 1q21 amplification in multiple myeloma].
Abramova TV; Obukhova TN; Mendeleeva LP; Pokrovskaya OS; Gribanova EO; Ryzhko VV; Grebenyuk LA; Nareyko MV; Solovyev MV; Votyakova OM; Kulikov SM; Rusinov MA; Savchenko VG
Ter Arkh; 2017; 89(7):32-38. PubMed ID: 28766538
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib-based regimens improve the prognosis of newly diagnosed MM patients with chromosomal aberrations except for del(17q13): A retrospective study from a single center.
Liu Z; Zeng Q; Xiang B
Medicine (Baltimore); 2021 May; 100(18):e25834. PubMed ID: 33950994
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J
Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
[TBL] [Abstract][Full Text] [Related]
24. [Detection of the Cytogenetic Aberrations in Multiple Myeloma by Using Microrray Comparative Genomic Hybridization].
Wang YF; Wang H; Xi LY; Zhang ZH; Wang J; Dong F; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1389-1395. PubMed ID: 30295256
[TBL] [Abstract][Full Text] [Related]
25. Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
Kiyota M; Kobayashi T; Fuchida S; Yamamoto-Sugitani M; Ohshiro M; Shimura Y; Mizutani S; Nagoshi H; Sasaki N; Nakayama R; Chinen Y; Sakamoto N; Uchiyama H; Matsumoto Y; Horiike S; Shimazaki C; Kuroda J; Taniwaki M
Int J Hematol; 2012 May; 95(5):516-26. PubMed ID: 22426624
[TBL] [Abstract][Full Text] [Related]
26. [A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
Wang GM; Yang GZ; Huang ZX; Zhong YP; Jin FY; Liao AJ; Wang XM; Fu ZZ; Liu H; Li XL; Zhou JF; Zhang X; Hu Y; Meng FY; Huang XJ; Chen WM; Lu J
Zhonghua Nei Ke Za Zhi; 2017 Jul; 56(7):500-506. PubMed ID: 28693058
[No Abstract] [Full Text] [Related]
27. [Cytogenetic abnormality of chromosome 13q14 in 112 patients with multiple myeloma detected by using LSI-RB1 and LSI-D13S319 probes].
Li F; Hu LP; An G; Xu Y; Wang YY; Xing LJ; Yi SH; Xie ZQ; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):917-21. PubMed ID: 22931654
[TBL] [Abstract][Full Text] [Related]
28. [Application of fluorescence in-situ hybridization technique in multiple myeloma].
Zhao Y; Zheng D; Li J; Zhu WT
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 38(5):459-64. PubMed ID: 19830857
[TBL] [Abstract][Full Text] [Related]
29. [Application of CD138 Immunomagnetic Bead Sorting Combined with Fluorescence in Situ Hybridization in Multiple Myeloma].
Li QZ; Tan K; Liu YX; Huang H; Zhang Y; Chen HM; Chen ZZ; Zhu ZW; Yang BH; Hu GY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1496-1500. PubMed ID: 36208255
[TBL] [Abstract][Full Text] [Related]
30. The clinical characteristics and prognosis of IGH deletion in multiple myeloma.
He H; Fu W; Jiang H; Du J; Zhou L; Zhang C; Xi H; Li R; Hou J
Leuk Res; 2015 May; 39(5):515-9. PubMed ID: 25817540
[TBL] [Abstract][Full Text] [Related]
31. [Expression of CD56 and CD19 in Patients with Newly Diagnosed Multiple Myeloma and Their Relationship with Karyotypes and Prognosis].
Qiu Q; Zhu P; Wang MJ; Lu XZ; Dong YJ; Sun YH; Wang LH; Zhang Y; Bu DF; Wang WS; Liang ZY; Liu W; Qiu ZX; Ou JP; Cen XN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1071-8. PubMed ID: 27531777
[TBL] [Abstract][Full Text] [Related]
32. [The comparison of three cytogenetic methods for detecting multiple myeloma].
Ren J; Yang LH; Li GX; Fan JL; Hou J
Zhonghua Nei Ke Za Zhi; 2009 Sep; 48(9):737-40. PubMed ID: 20079209
[TBL] [Abstract][Full Text] [Related]
33. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.
An G; Xu Y; Shi L; Shizhen Z; Deng S; Xie Z; Sui W; Zhan F; Qiu L
Haematologica; 2014 Feb; 99(2):353-9. PubMed ID: 24213147
[TBL] [Abstract][Full Text] [Related]
34. Fluorescence in situ hybridization analysis of chromosome aberrations in 60 Chinese patients with multiple myeloma.
Gao X; Li C; Zhang R; Yang R; Qu X; Qiu H; Xu J; Lu H; Li J; Chen L
Med Oncol; 2012 Sep; 29(3):2200-6. PubMed ID: 21611837
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of 1q21 Gain in Multiple Myeloma.
Chen D; Zhou D; Xu J; Zhou R; Ouyang J; Chen B
Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):e159-e164. PubMed ID: 30685183
[TBL] [Abstract][Full Text] [Related]
36. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.
Hao S; Lu X; Gong Z; Bassett RL; Hu S; Konoplev SN; Tang G; Li S; Xu J; Khanlari M; Lee HC; Manasanch EE; Weber DM; Orlowski RZ; Medeiros LJ; Lin P
Mod Pathol; 2021 Feb; 34(2):327-335. PubMed ID: 32908255
[TBL] [Abstract][Full Text] [Related]
37. [Clinical and experimental study of a multiple myeloma case with low hypodiploidy].
Bai SX; Pan JL; Xue YQ; Chen SN; Wu YF; Wang Y; Zhang J; Shen J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Jun; 29(3):343-6. PubMed ID: 22678804
[TBL] [Abstract][Full Text] [Related]
38. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
[TBL] [Abstract][Full Text] [Related]
39. Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains.
Chang H; Trieu Y; Qi X; Jiang NN; Xu W; Reece D
Leuk Res; 2011 Jan; 35(1):95-8. PubMed ID: 20537706
[TBL] [Abstract][Full Text] [Related]
40. [Cytogenetic study on 53 patients with multiple myeloma].
Jing Y; Fang MY; Jiang F; Lin S; Wang FT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):68-72. PubMed ID: 21362224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
